title: Drug delivery system of therapeutic oligonucleotides.
abstract: Therapeutic oligonucleotides are promising technologies. Nevertheless, improvement of their efficacy is an important issue. Introducing this drug delivery system (DDS) makes for a great enhancement for delivery of oligonucleotides to targeted tissue or cells. The strategy of DDS for therapeutic oligonucleotides is divided into four categories, A) single piece of oligonucleotide, B) oligonucleotide-ligand conjugate, C) oligonucleotide-polymer conjugate, and D) nanoparticle. In this review we will describe those basic concepts, especially for the technology of conjugating ligand. In addition, we developed a new technology, heteroduplex oligonucleotide (HDO), binding ligand-molecule to antisense oligonucleotide indirectly. We also outline α-tocopherol (a natural isomer of vitamin E) conjugated HDO.
authors.affiliation: Department of Neurology and Neurological Science, Graduate School, Tokyo Medical and Dental University.
authors.forename: Yutaro
authors.initials: Y
authors.lastname: Asami
authors.forename: Kotaro
authors.initials: K
authors.lastname: Yoshioka
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Nishina
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Nagata
authors.forename: Takanori
authors.initials: T
authors.lastname: Yokota
mesh_terms: D016503:Drug Delivery Systems; D006801:Humans; D009841:Oligonucleotides / Q000008:administration & dosage*; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage; D034741:RNA, Small Interfering / Q000008:administration & dosage; D024505:Tocopherols / Q000008:administration & dosage
chemical_list: D009841:Oligonucleotides; D016376:Oligonucleotides, Antisense; D034741:RNA, Small Interfering; D024505:Tocopherols